BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

C8 MediSensors, Inc. Closes $24 Million Preferred Stock Financing Furthering Momentum for 2012 Product Introduction


12/1/2011 7:18:41 AM

SAN JOSE, California , December 1, 2011 /PRNewswire/ --

Significant Investment From GE healthymagination Fund

C8 MediSensors, Inc. (http://www.c8medisensors.com), the leading company for noninvasive continuous glucose monitoring for diabetics, announced today that it has raised a total of [ $24 ] million through the sale of Preferred C stock. Recognising the revolutionary potential of C8 MediSensor's noninvasive technology to improve the lives of diabetics, existing investors as well as new investors including GE's healthymagination Fund made a significant investment that will accelerate C8 MediSensors' planned product introduction in 2012.

"Glucose monitoring is the most common method of monitoring diabetic care in the world. GE Healthcare has a solid monitoring business, one in which we focus on new and innovative ways to monitor patients in the most non-invasive way. C8 is a good strategic fit with GE Healthcare, given our common focus on clinical issues for the patient," said Thierry Leclercq , General Manager of GE Healthcare's Life Care Solutions business. "GE Healthcare's growing monitoring business must invest in areas that are most important to patients. A non-invasive way to monitor glucose can change the paradigm of diabetes care and improve the life of diabetics everywhere. We look forward to exploring ways to collaborate with the C8 team."

C8 MediSensors has successfully harnessed the potential of Raman spectroscopy to commercialise a non-invasive glucose monitor that improves the lives of diabetics by giving them a continuous view of their glucose levels without the pain, inconvenience and high cost of invasive glucose monitoring.

"We are diabetics helping diabetics. C8 MediSensors was co-founded by Jan Lipson , a PhD in physics who wanted to help his son, a Type 1 diabetic, by sparing him the pain of constant finger sticks. Another co-founder, Paul Zygielbaum , is a Type 2 diabetic," said Fred Toney , CFO of C8 MediSensors. "Furthermore, we are pleased to welcome GE, through its healthymagination Fund, as new investors in C8 MediSensors. GE's knowledge and breadth of reach throughout the healthcare vertical is a significant advantage to C8 MediSensors as we execute our business plan."

C8 MediSensors will introduce the new noninvasive continuous glucose monitor in the European Community in 2012, pending CE Mark regulatory approval.

About C8MediSensors

C8 MediSensors is the leader in noninvasive continuous glucose monitoring. Headquartered in San Jose CA , C8 MediSensors' breakthrough patent-protected technology gives people with diabetes a continuous view of their glucose levels, without the pain, inconvenience and high cost of invasive continuous glucose monitoring. Visit http://www.c8medisensors.com.

About the GE healthymagination Fund

The GE healthymagination Fund draws on capabilities from across GE Healthcare, GE Capital and GE Global Research, and has a global footprint.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom , GE Healthcare is a unit of General Electric Company (NYSE: GE - News). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit http://www.gehealthcare.com.

For our latest news, please visit http://newsroom.gehealthcare.com

About GE Capital

GE Capital offers consumers and businesses around the globe an array of financial products and services. For more information, visit http://www.gecapital.com or follow company news via Twitter (@GECapital).

This document contains forward-looking statements. Any statements in this document that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to C8's anticipated product sales and financing needs. These forward-looking statements are based upon C8's currentexpectations.Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with market conditions, customer demand for the product, and risks and uncertainties associated with C8's business and finances in general. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. C8 does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES